epocrates

Conference Highlights: The Endocrine Society annual meeting

June 11, 2024

ENDO 2024, The Endocrine Society’s annual conference, wrapped up on June 4, 2024. Below are selected highlights of the research presented at the meeting.

Updated vitamin D guideline

Newly updated Endocrine Society guidelines recommend against routine 25(OH)D testing in most groups and state that healthy adults under the age of 75 are unlikely to benefit from taking more than the recommended daily intake of vitamin D. Read more.

Reassuring long-term data on safety of metformin during pregnancy

Metformin appears safe to use for the management of diabetes during pregnancy according to new study results presented at ENDO 2024. Researchers collected 11 years’ worth of data and found no long-term adverse effects on children and their mothers for at least 11 years after childbirth. According to an Endocrine Society press release, this is the first study to examine the longer-term effects of metformin use during pregnancy. Read more.

Teprotumumab leads to sustained relief from thyroid eye disease symptoms

Teprotumumab, an insulin-like growth factor-I receptor inhibitor, demonstrated long-term improvements in thyroid eye disease signs and symptoms, according to data presented at the recent ENDO 2024 meeting. Among the 112 patients who received 7-8 infusions of teprotumumab for thyroid eye disease (TED) in the OPTIC and OPTIC-X studies, the long-term response as observed 51 weeks after therapy was similar to week 24 results in the controlled clinical trials. Read more.

New male birth control gel effective within one month, study finds

A male contraceptive gel combining testosterone and segesterone acetate (Nestorone) suppressed sperm production faster than similar experimental hormonal-based methods for male birth control. Read more.

Novel agent shows promise in congenital adrenal hyperplasia trial

Crinecerfont, an oral corticotropin-releasing factor type 1 receptor antagonist, lowered androstenedione levels in phase 2 congenital adrenal hyperplasia trials. Results from the phase 3 CAHtalyst trial were recently shared at the ENDO 2024 meeting. Read more.